Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding Ltd (OP: RHHBF )

332.06 +5.06 (+1.55%)
Streaming Delayed Price Updated: 1:55 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 335.00
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 327.00
Today's Range 332.06 - 335.00
52wk Range 243.42 - 368.43
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report
Novartis reportedly plans to cut 680 development jobs worldwide, separate from an 8,000-employee restructuring, aiming to reshape its workforce and tap local talent pools. 
Via Benzinga
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. 
Via Benzinga
Exposures COVID-19

Performance

YTD
+8.11%
+8.11%
1 Month
-4.77%
-4.77%
3 Month
+3.03%
+3.03%
6 Month
+13.49%
+13.49%
1 Year
+6.60%
+6.60%

More News

Read More
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
Via Benzinga
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
Via Benzinga
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Via Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
Via Benzinga
Exposures Product Safety
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
Via Benzinga
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
Via Benzinga
Exposures COVID-19
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
Via Benzinga
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Via Benzinga
Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares
Via Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Via Benzinga
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
Via Benzinga
Exposures COVID-19
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
Via Benzinga
Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer
Via Benzinga
Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time
Via Benzinga
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Via Benzinga
Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study
Via Benzinga
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Via Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
Via Benzinga
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
Via Benzinga
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
Via Benzinga
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
Via Benzinga
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
Via Benzinga
Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.